1. Short title This Act may be cited as the Greater Access to Contraceptive Options Act . 2. Applications for non-prescription contraceptive methods (a) Priority review of application The Secretary of Health and Human Services (referred to in this section as the Secretary ) shall give priority review to any supplemental application submitted under section 505(b), 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(b) , 360, 360e) for a self-administered contraceptive method to be marketed without being subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353(b)(1) ) or treated as a prescription device. (b) Fee waiver The Secretary shall waive the fee under section 736(a)(1) or 738(a)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379h(a)(1) ; 379j(a)(2)) (as applicable) with respect to a supplemental application that receives priority review under subsection (a). (c) Applicability This section applies with respect to a supplemental application described in subsection (a) that— (1) is submitted before the date of enactment of this Act and remains pending as of such date of enactment; or (2) is submitted after such date of enactment. (d) Self-Administered contraceptive method defined In this Act, the term self-administered contraceptive method means a drug or device (as those terms are defined in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 )) or combination product approved for use under the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 et seq. ) as a method of contraception that is administered without the intervention of a health care professional, including the birth control pill, patch, vaginal ring, or injection, such as depot medroxyprogesterone acetate.